Index | MSCI ACWI IMI Genomic Innovation Select ESG Screened 100 |
Investment focus | Equity, World, Health Care, Social/Environmental |
Fund size | EUR 3 m |
Total expense ratio | 0.30% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Sustainability | Yes |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 16.08% |
Inception/ Listing Date | 12 July 2022 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | Xtrackers |
Fund Structure | Company With Variable Capital (SICAV) |
UCITS compliance | Yes |
Administrator | State Street Custodial Services (Ireland) Limited |
Investment Advisor | DWS Investments UK Ltd |
Custodian Bank | State Street Custodial Services (Ireland) Limited |
Revision Company | Pricewaterhouse Coopers |
Fiscal Year End | 31 December |
Swiss representative | DWS CH AG |
Swiss paying agent | Deutsche Bank (Suisse) SA |
Germany | 30% tax rebate |
Switzerland | ESTV Reporting |
Austria | Tax Reporting Fund |
UK | UK Reporting |
Indextype | - |
Swap counterparty | - |
Collateral manager | |
Securities lending | Yes |
Securities lending counterparty |
Moderna, Inc. | 5.82% |
Lonza Group AG | 5.11% |
Thermo Fisher Scientific, Inc. | 4.85% |
ICON plc | 4.84% |
Danaher Corp. | 4.55% |
Regeneron Pharmaceuticals | 4.35% |
Abbott Laboratories | 4.33% |
Vertex Pharmaceuticals, Inc. | 4.32% |
Gilead Sciences, Inc. | 4.24% |
Agilent Technologies | 4.16% |
United States | 78.45% |
Switzerland | 10.17% |
Ireland | 4.84% |
China | 2.23% |
Other | 4.31% |
Health Care | 97.11% |
Basic Materials | 0.08% |
Other | 2.81% |
YTD | -0.04% |
1 month | +1.21% |
3 months | -4.01% |
6 months | +8.14% |
1 year | -2.96% |
3 years | - |
5 years | - |
Since inception (MAX) | -17.59% |
2023 | -7.06% |
2022 | - |
2021 | - |
2020 | - |
Volatility 1 year | 16.08% |
Volatility 3 years | - |
Volatility 5 years | - |
Return per risk 1 year | -0.18 |
Return per risk 3 years | - |
Return per risk 5 years | - |
Maximum drawdown 1 year | -18.34% |
Maximum drawdown 3 years | - |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -32.46% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
gettex | EUR | XGEN | - - | - - | - |
Borsa Italiana | EUR | XGEN | XGEN IM XGENEUIV | XGEN.MI XGENEURINAV=SOLA | |
London Stock Exchange | USD | XGEN | XGEN LN XGENUSIV | XGEN.L XGENUSDINAV=SOLA | |
London Stock Exchange | GBP | XGES | XGES LN XGENCHIV | XGES.L XGENCHFINAV=SOLA | |
SIX Swiss Exchange | CHF | XGEN | XGEN SW XGENGBIV | XGEN.S XGENGBPINAV=SOLA | |
XETRA | EUR | XGEN | XGEN GR | XGEN.DE |
Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
---|---|---|---|---|
iShares Healthcare Innovation UCITS ETF | 958 | 0.40% p.a. | Accumulating | Sampling |
VanEck Genomics and Healthcare Innovators UCITS ETF A | 6 | 0.35% p.a. | Accumulating | Full replication |